Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Total Non-Current Liabilities (2016 - 2025)

Historic Total Non-Current Liabilities for Theravance Biopharma (TBPH) over the last 13 years, with Q3 2025 value amounting to $182.5 million.

  • Theravance Biopharma's Total Non-Current Liabilities rose 1026.87% to $182.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $182.5 million, marking a year-over-year increase of 1026.87%. This contributed to the annual value of $176.7 million for FY2024, which is 9745.04% up from last year.
  • Theravance Biopharma's Total Non-Current Liabilities amounted to $182.5 million in Q3 2025, which was up 1026.87% from $199.6 million recorded in Q2 2025.
  • In the past 5 years, Theravance Biopharma's Total Non-Current Liabilities registered a high of $746.3 million during Q1 2021, and its lowest value of $89.5 million during Q4 2023.
  • For the 5-year period, Theravance Biopharma's Total Non-Current Liabilities averaged around $334.3 million, with its median value being $176.7 million (2024).
  • Its Total Non-Current Liabilities has fluctuated over the past 5 years, first tumbled by 8596.42% in 2022, then surged by 9745.04% in 2024.
  • Over the past 5 years, Theravance Biopharma's Total Non-Current Liabilities (Quarter) stood at $638.4 million in 2021, then plummeted by 85.96% to $89.6 million in 2022, then fell by 0.11% to $89.5 million in 2023, then soared by 97.45% to $176.7 million in 2024, then increased by 3.25% to $182.5 million in 2025.
  • Its Total Non-Current Liabilities stands at $182.5 million for Q3 2025, versus $199.6 million for Q2 2025 and $176.3 million for Q1 2025.